A SPAC I Acquisition Corp. (NASDAQ:ASCA) plans to merge with Southeast Asian fertility products and services supplier NewGenIVF.
The deal, which is anticipated to near in Q3, estimates NewGenIVF’s undertaking worth at round $50M. Stocks of the mixed corporate are expected to business on Nasdaq.
NewGenIVF gives complete fertility therapies and products and services, together with egg/sperm donation and surrogacy, via its clinics based totally in Thailand, Cambodia and Kyrgyzstan.
A SPAC I went public in February 2022, elevating $60M.